Prolonged L-dopa treatment in Parkinson's disease (PD) often leads to the expression of abnormal involuntary movements known as L-dopa-induced dyskinesia. Recently, dramatic 80 Hz oscillatory local field potential (LFP) activity within the primary motor cortex has been linked to dyskinetic symptoms in a rodent model of PD and attributed to stimulation of cortical dopamine D1 receptors. To characterize the relationship between high gamma (70-110 Hz) cortical activity and the development of L-dopa-induced dyskinesia, cortical LFP and spike signals were recorded in hemiparkinsonian rats treated with L-dopa for 7 days, and dyskinesia was quantified using the abnormal involuntary movements (AIMs) scale. The relationship between high gamma and dyskinesia was further probed by assessment of the effects of pharmacological agents known to induce or modulate dyskinesia expression. Findings demonstrate that AIMs and high gamma LFP power increase between days 1 and 7 of L-dopa priming. Notably, high beta (25-35 Hz) power associated with parkinsonian bradykinesia decreased as AIMs and high gamma LFP power increased during priming. After priming, rats were treated with the D1 agonist SKF81297 and the D2 agonist quinpirole. Both dopamine agonists independently induced AIMs and high gamma cortical activity that were similar to that induced by L-dopa, showing that this LFP activity is neither D1 nor D2 receptor specific. The serotonin 1A receptor agonist 8-OH-DPAT reduced L-dopa-and DA agonistinduced AIMs and high gamma power to varying degrees, while the serotonin 1A antagonist WAY100635 reversed these effects. Unexpectedly, as cortical high gamma power increased, phase locking of cortical pyramidal spiking to high gamma oscillations decreased, raising questions regarding the neural substrate(s) responsible for high gamma generation and the functional correlation between high gamma and dyskinesia.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder that is caused by the death of dopaminergic neurons in the basal ganglia. PD primarily affects the motor system, inducing rigidity, slowness of movement, tremors and lack of coordination. Development of these motor impairments has been associated with the emergence of synchronized and oscillatory activity in the beta frequency range (13-35 Hz) in the motor cortex and basal ganglia of PD patients (Brown, 2003; Brittain and Brown, 2014; Brown et al., 2001; Levy et al., 2002; Priori et al., 2004; Weinberger et al., 2006; Kuhn et al., 2005) and hemiparkinsonian rats (Sharott et al., 2005; Avila et al., 2010; Brazhnik et al., 2012 Brazhnik et al., , 2014 Delaville et al., 2015) . Increased oscillatory activity has also been observed at lower frequencies in parkinsonian primates (Bergman et al., 1994; Gatev et al., 2006; Devergnas et al., 2014; Raz et al., 2000; Rivlin-Etzion et al., 2010) .
Early stage PD patients are often treated with dopamine (DA) receptor agonists; however, the anti-parkinsonian efficacy of these agonists is somewhat limited and most patients are ultimately treated with levodopa (L-dopa), the precursor to DA. Unfortunately, prolonged L-dopa treatment often leads to the development of abnormal involuntary movements, otherwise known as L-dopa-induced dyskinesia (Jankovic, 2005) . Though DA agonists are less likely to induce this side effect (Chondrogiorgi et al., 2014; Stathis et al., 2015) , they can also Abbreviations: 5-HT, serotonin; 6-OHDA, 6-hydroxydopamine; 8-OH-DPAT, (+)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide; AIMs, abnormal involuntary movements; ALO, axial, limb, and orolingual; benserazide, DL-serine 2-(2,3,4-trihydroxybenzyl) hydrazide hydrochloride; Aq, aqueduct (Sylvius); DA, dopamine; DPAT, 8-OH-DPAT; FFT, fast Fourier-transform; FTG, finely-tuned gamma; GPi, globus pallidus internal segment; i.p., intraperitoneally; L-dopa, levodopa; LFP, local field potential; PCA, principal component analysis; PING, pyramidal-interneuronal gamma; PD, Parkinson's disease; quinpirole, (−)-quinpirole hydrochloride; RM, repeated-measures; RMS, root mean square; SKF81297, R(+)-SKF-81297 hydrobromide; SN, substantia nigra; SNR, signal-to-noise ratio; STN, subthalamic nucleus; STWA, spike-triggered waveform average; TH, tyrosine hydroxylase; WAY, WAY100635; WAY100635, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt.
